Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $79M | $10M | $110M | 0.6% | 13.9% | -116.8% |
| 2024 | $1.3B | $40M | $-57M | $86M | -4.0% | 18.5% | -69.2% |
| 2023 | $1.1B | $-105M | $-186M | $-57M | -13.0% | 22.8% | -13.6% |
| 2022 | $860M | $-144M | $-216M | $-26M | -14.2% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 1,424.28 |
| Operating Revenue | 1,424.28 |
| Cost Of Revenue | 963.19 |
| Gross Profit | 461.10 |
| Operating Expense | 436.95 |
| Selling General And Administration | 382.20 |
| Total Expenses | 1,400.14 |
| Operating Income | 24.15 |
| Total Operating Income As Reported | 24.15 |
| EBITDA | 78.78 |
| Normalized EBITDA | 78.78 |
| EBIT | 24.02 |
| Interest Expense | 11.66 |
| Net Interest Income | -11.66 |
| Other Non Operating Income Expenses | -0.12 |
| Other Income Expense | -0.12 |
| Interest Expense Non Operating | 11.66 |
| Net Non Operating Interest Income Expense | -11.66 |
| Pretax Income | 12.36 |
| Tax Provision | 2.70 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | 9.66 |
| Net Income From Continuing And Discontinued Operation | 9.66 |
| Net Income From Continuing Operation Net Minority Interest | 9.66 |
| Net Income | 9.66 |
| Net Income Common Stockholders | 9.66 |
| Net Income Including Noncontrolling Interests | 9.66 |
| Normalized Income | 9.66 |
| Diluted NI Availto Com Stockholders | 9.66 |
| Basic Average Shares | 386.02 |
| Diluted Average Shares | 391.14 |
| Reconciled Depreciation | 54.75 |
| Reconciled Cost Of Revenue | 963.19 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Special Income Charges | 0 |
| Restructuring And Mergern Acquisition | 0 |
| Depreciation Amortization Depletion Income Statement | 54.75 |
| Depreciation And Amortization In Income Statement | 54.75 |
| General And Administrative Expense | 382.20 |
| Other Gand A | 382.20 |
| Otherunder Preferred Stock Dividend | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| LifeStance Health Group, Inc.this co. | LFST | $2.9B | 301.90 | 1.92 | 0.6% | 39.90 |
| Alignment Healthcare, Inc. | ALHC | $3.1B | - | 17.38 | -0.4% | 62.69 |
| Dyne Therapeutics, Inc. | DYN | $3.0B | -6.82 | 3.13 | -45.9% | -5.30 |
| Warby Parker Inc. | WRBY | $3.0B | 1803.71 | 8.05 | 0.4% | 64.67 |
| Adaptive Biotechnologies Corporation | ADPT |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $2.9B |
| - |
| 13.23 |
| -27.2% |
| - |
| GRAIL, Inc. | GRAL | $2.9B | -6.99 | 1.11 | -15.8% | -7.04 |
| Brookdale Senior Living Inc. | BKD | $2.8B | -10.81 | -63.45 | 587.0% | 23.48 |
| Soleno Therapeutics, Inc. | SLNO | $2.8B | 132.26 | 6.14 | 4.6% | 96.72 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.7B | -170.10 | 14.49 | -8.5% | 1582.53 |
| Peer Median | - | -6.91 | 7.09 | -4.5% | 62.69 | |